Pharmacological properties
Pharmacodynamics. The main action of insulin is to regulate glucose metabolism. In addition, insulin affects some anabolic and anti-catabolic processes in various tissues. In muscle tissues, such effects include increased synthesis of glycogen, fatty acids, glycerol, and protein, as well as increased amino acid uptake and decreased glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism, and amino acid removal.
Pharmacokinetics. Farmasulin H 30/70 is a mixture of short-acting insulin in combination with medium-acting insulin.
The drug Farmasulin H 30/70 is human insulin, which is produced using recombinant DNA technologies.
Insulin pharmacokinetics do not reflect the metabolic activity of the hormone.
The onset of effect of Farmasulin H 30/70 is 30 minutes after administration. Peak C max is observed 1-8.5 hours after injection. The duration of the hypoglycemic effect is 14-15 hours, sometimes up to 24 hours. During toxicological studies, no serious harmful effects associated with the use of the drug were identified.
There may be variability in the duration of insulin action or its intensity in different patients. Individual characteristics depend on factors such as dose volume, temperature at the injection site and the patient's level of physical activity.
Indication
Treatment of diabetic patients who require insulin to maintain normal blood glucose levels.
Application
The dose and time of administration are determined by the doctor, taking into account the personal needs of each patient.
Pharmasulin H 30/70 is administered subcutaneously.
Farmasulin H 30/70 cannot be administered intravenously!
Farmasulin H 30/70 can be administered intramuscularly, although this method of administration is not recommended.
Subcutaneous injection should be given in the shoulder, thigh, buttocks or abdomen. Injections should be given in different parts of the body so that the same part is not injected more than once a month. Avoid inserting the needle into a blood vessel. Do not rub the injection site after administration. The patient should be thoroughly instructed on the injection technique.
1. Instructions for use of the drug.
Cartridges: The suspension for injection in 3 ml cartridges must be used with a pen injector that is CE marked in accordance with the recommendations of the pen injector manufacturer.
Preparation of the dose. Before use, Farmasulin H 30/70 should be resuspended by rolling the cartridge between the palms of your hands 10 times and turning it 180 ° 10 times until the suspension becomes uniformly cloudy or milky. If the liquid does not have the desired appearance, the operation should be repeated until the contents of the cartridge are completely mixed. The cartridges contain a glass ball to facilitate mixing. Do not shake the cartridge vigorously, as this may cause foaming and interfere with accurate dose measurement. Regularly check the appearance of the cartridge contents and do not use it if the suspension contains lumps or if white particles stick to the bottom or walls of the cartridge, making the glass opaque.
To load the cartridge into the pen injector, attach the needle, and inject insulin, refer to the pen injector manufacturer's instructions for administering insulin.
The cartridges are not intended for mixing with other insulins.
Empty cartridges cannot be reused.
Vials. It is necessary to regularly check the appearance of the contents of the vial and do not use the drug if, after shaking, the suspension contains flakes or if white particles adhere to the bottom or walls of the vial, creating a frosty pattern effect.
Use a syringe with markings that match the dose of insulin prescribed by your doctor. It is important to use a syringe of the same type and brand. Carelessness when using a syringe can lead to incorrect insulin dosing.
dose preparation
1) Immediately before injection, roll the vial of insulin suspension between your palms so that its turbidity becomes uniform throughout the entire volume of the vial. Do not shake the vial vigorously, as this may cause foaming, which will interfere with accurate dose measurement.
2) Withdraw insulin from the vial by piercing the stopper with a sterile syringe needle, previously wiped with alcohol. The injected insulin should be at room temperature.
3) Draw air into the syringe to the mark corresponding to the required dose of insulin, and then release the air into the vial.
4) Turn the syringe with the vial upside down and draw up the required dose of insulin.
5) Remove the needle from the vial. Release the air from the syringe and check the correct dose of insulin.
When performing the injection, the rules of asepsis should be observed. To prevent purulent-inflammatory complications, do not reuse a disposable syringe.
2. Administer the drug. Administer the required dose of insulin according to your doctor's instructions.
Injections should be performed in different areas of the body, with the aim of injecting into the same place no more than once a month.
Children. The dose, administration schedule, and number of injections in children are determined by the doctor based on specific needs and in accordance with each specific case.
Hypoglycemia, hypersensitivity to FARMASULIN n 30/70 and any excipients of the drug, except in cases of desensitization therapy. Intravenous administration is contraindicated.
Side effects
Hypoglycemia is the most common side effect of insulin therapy in patients with diabetes. Severe hypoglycemia can lead to loss of consciousness, and in some extreme cases, to death. Data on the frequency of hypoglycemia are not provided, as it is related to the dose of insulin and other factors, such as the patient's diet and level of physical activity.
Local allergic reactions may include changes in the injection site, redness, swelling, and itching. They usually last from a few days to a few weeks. In some cases, these reactions are not related to insulin but to other factors, such as irritants in skin cleansers or lack of experience in giving injections.
Systemic allergy is a potentially serious side effect and is a generalized form of allergy to insulin, including rash on the entire body, shortness of breath, wheezing, decreased blood pressure, increased heart rate and sweating. Severe cases of generalized allergy are life-threatening. In some exceptional cases of severe allergy to Farmasulin H 30/70, appropriate measures should be taken immediately. It may be necessary to replace insulin or conduct desensitization therapy.
Lipodystrophy may rarely occur at the injection site.
Insulin resistance: Cases of edema have been reported with insulin therapy, particularly in cases with previously reduced metabolism that improved with intensive insulin therapy.
Special instructions
Any change in type or brand of insulin should be made under close medical supervision. Changes in strength, brand (corresponding to a specific manufacturer), type (rapid-acting, intermediate-acting, slow-acting), type (animal insulin, human insulin, human insulin analogue) and/or method of preparation (recombinant DNA insulin as opposed to animal insulin) may require a change in dose.
The dosage for patients treated with human insulin may differ from that used for patients treated with animal insulins. If dose adjustments are necessary, these may be made with the first dose or over the first few weeks or months.
In some patients who have experienced hypoglycaemic reactions after being transferred from animal insulin to human insulin, the early warning symptoms of hypoglycaemia have been less pronounced or different from those previously experienced by these patients with animal insulin. Patients with significant improvement in blood glucose levels (e.g. due to intensification of insulin therapy) may no longer develop some or all of the early warning symptoms of hypoglycaemia and should be advised to do so. The early warning symptoms of hypoglycaemia may also be different or less pronounced in patients with long-standing diabetes mellitus and diabetic neuropathy or in patients taking other medicinal products, such as β-blockers, in addition to their current treatment.
Hypoglycemia or hyperglycemic reactions that have not been corrected can lead to loss of consciousness, coma, or death.
Incorrect dosing or discontinuation of treatment (especially in patients with insulin-dependent diabetes mellitus) may lead to hyperglycemia and potentially fatal diabetic ketoacidosis.
Antibodies may be produced during treatment with human insulin, although in lower concentrations than with purified insulin of animal origin.
The need for insulin changes significantly in cases of impaired function of the adrenal glands, pituitary gland, thyroid gland, renal or hepatic failure.
Insulin requirements may also increase during illness or emotional stress.
The need for dose adjustment may arise if the intensity of physical activity or usual diet changes.
Combined use with pioglitazone. Cases of heart failure have been reported with the combined use of pioglitazone with insulin, especially in patients with risk factors for heart failure. This information should be taken into account when prescribing the combination of Farmasulin H 30/70 with pioglitazone. If this combination is used, the patient should be monitored for signs and symptoms of heart failure, weight gain and edema. Treatment with pioglitazone should be discontinued if cardiac symptoms worsen.
Strict control of blood glucose levels and overall health is vital for pregnant women with diabetes.
Women with diabetes may need to adjust their insulin doses and/or diet while breastfeeding.
Ability to influence the reaction speed when driving or using other mechanisms. Hypoglycemia can negatively affect concentration and reflex reactions, i.e. it is a risk factor in situations that require these qualities, for example, when driving a car or operating mechanical devices.
Patients should be advised to take precautions before driving to avoid worsening hypoglycaemia, particularly if early warning signs of hypoglycaemia are absent or subtle, or if worsening hypoglycaemia is frequent. In such circumstances, they should not drive.
Interactions
Some medicines affect glucose metabolism. The doctor should be informed of any concomitant treatment taken simultaneously with human insulin.
If it is necessary to take other medications, you should consult a doctor.
The need for insulin may increase when using drugs with hyperglycemic activity, such as oral contraceptives, corticosteroids, thyroid hormones and growth hormone, danazol, β 2 -sympathomimetics (e.g. ritodrine, salbutamol, terbutaline), thiazides.
Insulin requirements may be reduced by the use of medicinal products with hypoglycaemic activity, such as oral hypoglycaemic agents, salicylates (e.g. acetylsalicylic acid), sulpha antibiotics, some antidepressants (MAO inhibitors), some ACE inhibitors (captopril, enalapril), angiotensin II receptor blockers, non-selective β-adrenoceptor blockers or alcohol.
Somatostatin analogs (octreotide, lanreotide) can both increase and decrease the need for insulin.
Incompatibility. Farmasulin H 30/70 should not be mixed with insulins from other manufacturers and insulins of animal origin.
Overdose
Symptoms. There is no specific definition for insulin overdose, as blood glucose levels are influenced by complex interactions between plasma insulin levels, glucose availability, and other metabolic processes. Hypoglycemia may be caused by excess insulin, taking into account the intensity of carbohydrate intake and the level of physical activity.
Symptoms of hypoglycemia include apathy, confusion, palpitations, headache, increased sweating, and vomiting.
Treatment. In cases of mild hypoglycemia, patients are given glucose or other sugar-containing products orally. In cases of moderate hypoglycemia, patients should be treated with i.m. or s.c. glucagon followed by carbohydrate with food after adequate recovery of the patient's condition. However, if glucagon is not available or the patient does not respond to its administration, glucose should be administered i.v. Immediately after regaining consciousness, the patient should eat. It may be necessary to continue giving the patient carbohydrates and to continue monitoring the blood glucose level, since hypoglycemia may occur after clinical recovery.
Storage conditions
In the original packaging at a temperature of 2-8 °C (in a refrigerator). Do not freeze. The shelf life of the drug in cartridges and vials after opening is 28 days at a temperature of 15-25 °C, protecting from overheating and sunlight. Cartridges in use should not be kept in the refrigerator.
